bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration

Marcy-l’Étoile, France, October 15^th, 2024 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS^® VITAMIN B₁₂ TOTAL, an automated quantitative test for use on the VIDAS^® immunoassay instruments, for the measurement of total Vitamin B₁₂ concentration in human serum or plasma.

Vitamin B_12, also known as cobalamin, is essential for well-being and cellular metabolism. This micronutrient, mainly present in food products from animal origin – particularly meat, fish, eggs and dairy – is required for normal functioning of the central nervous system, DNA synthesis and healthy red blood cell formation.

Measuring levels of vitamin B₁₂ may help optimize patients’ care since its deficiency can be associated with anemia or neurological symptoms including cognitive difficulties or impaired gait. VIDAS^® VITAMIN B₁₂ TOTAL is an automated quantitative test to aid in the assessment of vitamin B₁₂ status in adults with suspected vitamin B₁₂ deficiency or at risk for low levels of vitamin B₁₂.

This new assay is for use on all VIDAS^® immunoanalysers that provide laboratory personnel with increased throughput and full traceability of test results. VIDAS^® VITAMIN B₁₂ TOTAL completes the VIDAS^® routine test menu, reinforcing the family of assays targeting anemia.

“As it enters a fourth decade, VIDAS^® remains a core focus of the bioMérieux immunoassay strategy with continued R&D investment in new product innovation. VIDAS^® VITAMIN B₁₂ TOTAL perfectly complements our comprehensive VIDAS^® portfolio that also includes infectious diseases, emergency, and critical care assays. The launch of VIDAS^® VITAMIN B₁₂ TOTAL is a testament to bioMérieux’s on-going commitment to provide value-add diagnostic solutions to lab and healthcare professionals for optimized patient care,” commented Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux.

The commercial launch of VIDAS^® VITAMIN B₁₂ TOTAL is planned in select countries at the end of 2024, with an extended rollout in Q1 2025.